Universal Health Services
UHS
$177.26
+2.54%
Universal Health Services, Inc. (UHS) is a leading healthcare services provider operating a vast network of behavioral health centers, acute care hospitals, and outpatient facilities across the United States and the UK. As a major player in the for-profit hospital industry, UHS distinguishes itself with a strong focus on behavioral health, which generates over half of its pretax profits despite contributing less than half of total revenue. The current investor narrative centers on the company's strategic acquisition of Talkspace to expand into digital behavioral healthcare, a move that has sparked both optimism for growth and caution regarding near-term integration costs. Additionally, UHS's stock has experienced significant volatility over the past year, with a sharp decline followed by a recent recovery, prompting debates about its valuation and long-term growth prospects.…
UHS
Universal Health Services
$177.26
Related headlines
Investment Opinion: Should I buy UHS Today?
We rate UHS as a Buy. The stock is trading at a forward PE of 7.4x, which is a significant discount to the industry average, and the PEG ratio of 0.26 indicates that the market is not fully pricing in the company's growth prospects. The analyst consensus is Buy with an average price target of $193.94, implying a 9.4% upside, and the high target of $290 suggests substantial upside potential if the Talkspace acquisition succeeds. The company's revenue growth of 9.7% YoY and strong free cash flow of $894M TTM support the thesis that the stock is undervalued.
Sign up to view all
UHS 12-Month Price Forecast
The AI assessment is bullish on UHS, driven by its compelling valuation and strong revenue growth. The stock trades at a forward PE of 7.4x, which is a 38% discount to its 5-year average, and the PEG ratio of 0.26 suggests the market is not fully pricing in growth. However, the medium confidence reflects the uncertainty around the Talkspace integration and the stock's negative momentum. If the company can execute on its growth strategy and maintain margins, the stock could re-rate higher. Key factors to watch include quarterly earnings, margin trends, and integration progress. A downgrade to neutral would occur if revenue growth falls below 5% or if operating margins decline below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Universal Health Services's 12-month outlook, with a consensus price target around $193.94 and implied upside of +9.4% versus the current price.
Average Target
$193.94
0 analysts
Implied Upside
+9.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$166 - $290
Analyst target range
UHS is covered by 17 analysts, with a consensus recommendation of 'Buy' and a mean rating of 2.4 (where 1 is Strong Buy and 5 is Sell). The average price target is $193.94, implying an upside of 9.4% from the current price of $177.26. The distribution of ratings includes 10 Buy, 6 Hold, and 1 Sell, reflecting a generally bullish sentiment but with some caution. The target price range spans from $166.00 (low) to $290.00 (high), with the high target suggesting a potential 63.6% upside, likely assuming successful integration of Talkspace and continued strong performance in behavioral health. The low target, however, implies a 6.4% downside, possibly pricing in margin compression or operational setbacks. Recent institutional actions show a mix of ratings, with Barclays downgrading from Overweight to Equal Weight in July 2026, while TD Cowen and UBS maintain Buy ratings, indicating some divergence in analyst views.
Drowning in data?
Find the real signal!
Bulls vs Bears: UHS Investment Factors
UHS presents a classic value-versus-momentum dilemma. The stock is fundamentally undervalued with a forward PE of 7.4x, a PEG of 0.26, and strong revenue growth of 9.7% YoY, but it has been in a severe downtrend, underperforming the market by 24 percentage points over the past year. The bull case rests on the high-margin behavioral health franchise and the growth potential of the Talkspace acquisition, while the bear case is driven by operational margin pressure, regulatory risks, and negative price momentum. Currently, the evidence slightly favors the bulls due to the compelling valuation and analyst upside, but the key tension is whether the Talkspace integration can be executed without significant margin dilution. If integration costs prove manageable and revenue synergies materialize, the stock could re-rate higher; if not, the stock may remain range-bound or decline further.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 9.7% YoY to $4.495B, with sequential acceleration from $4.284B in Q2 2025. This indicates robust demand across acute care and behavioral health segments.
- Undervalued on Multiple Metrics: Trailing PE of 9.3x and forward PE of 7.4x are well below the 5-year historical range (7x-18x). PEG ratio of 0.26 suggests the stock is trading at a significant discount to its growth prospects.
- High-Margin Behavioral Health Focus: Behavioral health generates over 55% of pretax profits despite contributing less than half of revenue, providing a high-margin, defensible business mix that supports profitability.
- Analyst Consensus Buy: With 17 analysts, the consensus is Buy (mean rating 2.4) and the average price target of $193.94 implies 9.4% upside. The high target of $290 suggests potential 63.6% upside if the Talkspace integration succeeds.
Bearish
- Significant Underperformance vs. Market: UHS stock fell 3.6% over the past year while the S&P 500 gained 20.5%, underperforming by 24.1 percentage points. The 6-month decline of -23.1% highlights persistent negative momentum.
- High Volatility and Drawdown Risk: The stock experienced a max drawdown of -42.19% from its 52-week high of $246.33 to the low of $140.08. Beta of 1.063 indicates higher volatility than the market, amplifying downside risk.
- Margin Pressure from Acquisition: The Talkspace acquisition is expected to introduce near-term integration costs and margin pressures. Q1 2026 operating margin was 11.2%, down from 11.5% in Q4 2025, indicating potential cost headwinds.
- Regulatory and Tariff Risks: The Trump administration's threat of 100% tariffs on drugmakers without pricing deals could increase input costs for healthcare providers. This macro risk could pressure margins and earnings.
UHS Technical Analysis
The prevailing price trend for UHS over the past year has been a pronounced downtrend, with the stock declining 3.6% over the last 12 months, significantly underperforming the S&P 500's gain of 20.5%. The current price of $177.26 sits at 72% of its 52-week range (low of $140.08, high of $246.33), indicating that the stock is trading closer to its lows than its highs, which suggests a bearish sentiment and potential value opportunity or continued weakness. The 6-month price change of -23.1% underscores the severity of the recent selloff, though the stock has shown signs of stabilization in recent weeks.
Beta
1.06
1.06x market volatility
Max Drawdown
-42.2%
Largest decline past year
52-Week Range
$140-$246
Price range past year
Annual Return
-3.6%
Cumulative gain past year
| Period | UHS Return | S&P 500 |
|---|---|---|
| 1m | +18.7% | +3.6% |
| 3m | +12.3% | +2.7% |
| 6m | -23.1% | +11.4% |
| 1y | -3.6% | +18.7% |
| ytd | -19.4% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UHS Fundamental Analysis
UHS has demonstrated robust revenue growth, with the most recent quarter (Q1 2026) reporting revenue of $4.495 billion, a 9.7% year-over-year increase. This growth is driven by both its acute care and behavioral health segments, with acute care contributing $2.61 billion and behavioral health $1.88 billion in the latest quarter. The company's revenue trajectory has been consistently positive, with sequential growth from $4.284 billion in Q2 2025 to $4.496 billion in Q1 2026, indicating accelerating demand for its services. The acquisition of Talkspace is expected to further bolster growth in the digital behavioral health space, though it may also introduce near-term margin pressures.
Quarterly Revenue
$4.5B
2026-03
Revenue YoY Growth
+9.7%
YoY Comparison
Gross Margin
14.6%
Latest Quarter
Free Cash Flow
$894018000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UHS Overvalued?
Given UHS's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 9.3x, while the forward PE is 7.4x, indicating that the market expects earnings growth, which is supported by the PEG ratio of 0.26. This low PEG suggests the stock is undervalued relative to its growth prospects. Compared to the industry average, UHS trades at a significant discount; for instance, its EV/EBITDA of 7.0x is well below the sector's typical range, and its PS ratio of 0.80 is substantially lower than the industry average, reflecting a value-oriented valuation. Historically, UHS's current PE is near the lower end of its 5-year range (which has fluctuated between roughly 7x and 18x), indicating that the market is pricing in conservative expectations, possibly due to concerns about regulatory changes or integration risks from the Talkspace acquisition.
PE
9.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~18x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. UHS carries a debt-to-equity ratio of 0.76, which is moderate but not excessive, and interest expenses of $36M in Q1 2026 are manageable. However, the company's operating margin has been volatile, dipping to 11.2% in Q1 2026 from 11.5% in Q4 2025, and the Talkspace acquisition will likely pressure margins in the near term due to integration costs. Revenue concentration in behavioral health (over 55% of pretax profits) exposes the company to regulatory changes in mental health reimbursement. Additionally, the company's free cash flow of $894M TTM is positive, but the payout ratio of only 3.4% suggests limited dividend growth potential, which may disappoint income investors.
